What is Pharmazz?
Headquartered in Willowbrook, Illinois, and established in 2010, Pharmazz, Inc. operates as a Delaware-based biopharmaceutical entity dedicated to the discovery and development of innovative therapies. The company maintains a robust international footprint, notably through its subsidiary, Pharmazz India Pvt Ltd, which facilitates its global research and distribution capabilities. Pharmazz focuses primarily on critical care medicine and neurological disorders, leveraging proprietary platforms to bring novel treatments to market. Its market position is defined by a commitment to rigorous scientific inquiry and the pursuit of therapeutic solutions that address severe, life-threatening conditions, positioning the firm as a key player in the evolving landscape of specialized medicine.
How much funding has Pharmazz raised?
Pharmazz has raised a total of $40.3M across 3 funding rounds:
Private Equity
$15M
Private Equity
$25M
Stock/Share Issuance
$250K
Private Equity (2024): $15M with participation from Sun Pharma
Private Equity (2025): $25M led by Sun Pharma
Stock/Share Issuance (2026): $250K, investors not publicly disclosed
Key Investors in Pharmazz
Sun Pharma
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is headquartered in Mumbai, India.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Pharmazz?
With the recent influx of capital, Pharmazz is well-positioned to accelerate its late-stage clinical programs and expand its commercial reach. The strategic deployment of these funds will likely prioritize the scaling of manufacturing processes and the strengthening of its global supply chain, particularly within the Indian market. As the company moves forward, stakeholders can expect an increased emphasis on regulatory filings and the potential for strategic partnerships to enhance the distribution of its therapeutic pipeline. The current enterprise-level funding environment provides the necessary stability for Pharmazz to pursue long-term value creation while continuing to address the complex challenges inherent in neurological and critical care drug development.
See full Pharmazz company page
